SUPN
Income statement / Annual
Last year (2023), Supernus Pharmaceuticals, Inc.'s total revenue was $607.52 M,
a decrease of 8.95% from the previous year.
In 2023, Supernus Pharmaceuticals, Inc.'s net income was $1.32 M.
See Supernus Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$607.52 M
|
$667.24 M
|
$579.78 M
|
$520.40 M
|
$392.76 M
|
$408.90 M
|
$302.24 M
|
$215.00 M
|
$144.43 M
|
$122.05 M
|
| Cost of Revenue |
$83.78 M |
$87.22 M |
$75.06 M |
$52.46 M |
$16.66 M |
$15.36 M |
$15.22 M |
$11.99 M |
$8.42 M |
$5.76 M |
| Gross Profit |
$523.74 M |
$580.02 M |
$504.71 M |
$467.94 M |
$376.10 M |
$393.54 M |
$287.02 M |
$203.02 M |
$136.00 M |
$116.29 M |
| Gross Profit Ratio |
0.86 |
0.87 |
0.87 |
0.9 |
0.96 |
0.96 |
0.95 |
0.94 |
0.94 |
0.95 |
| Research and Development
Expenses |
$91.59 M
|
$74.55 M
|
$90.47 M
|
$75.96 M
|
$69.10 M
|
$89.21 M
|
$49.58 M
|
$42.79 M
|
$29.14 M
|
$19.59 M
|
| General & Administrative
Expenses |
$236.66 M
|
$109.43 M
|
$105.05 M
|
$65.92 M
|
$117.63 M
|
$116.59 M
|
$104.11 M
|
$84.11 M
|
$69.90 M
|
$57.67 M
|
| Selling & Marketing
Expenses |
$99.70 M
|
$267.79 M
|
$199.71 M
|
$134.75 M
|
$40.80 M
|
$43.30 M
|
$33.80 M
|
$21.90 M
|
$19.30 M
|
$14.80 M
|
| Selling, General &
Administrative Expenses |
$336.36 M
|
$377.22 M
|
$304.76 M
|
$200.68 M
|
$158.43 M
|
$159.89 M
|
$137.91 M
|
$106.01 M
|
$89.20 M
|
$72.47 M
|
| Other Expenses |
$101.06 M |
$82.63 M |
$29.99 M |
$15.70 M |
$0.00 |
$0.00 |
$0.00 |
-$15,000.00 |
$38,000.00 |
$39,000.00 |
| Operating Expenses |
$529.01 M |
$534.40 M |
$425.22 M |
$292.34 M |
$227.52 M |
$249.10 M |
$187.48 M |
$148.80 M |
$118.34 M |
$92.06 M |
| Cost And Expenses |
$612.79 M |
$621.62 M |
$500.28 M |
$344.80 M |
$244.18 M |
$264.45 M |
$202.70 M |
$160.79 M |
$126.76 M |
$97.82 M |
| Interest Income |
$10.45 M |
$21.69 M |
$10.57 M |
$18.70 M |
$21.62 M |
$13.84 M |
$2.86 M |
$1.48 M |
$643,000.00 |
$387,000.00 |
| Interest Expense |
$2.42 M |
$7.07 M |
$23.42 M |
$23.75 M |
$22.71 M |
$18.11 M |
$1.57 M |
$5.09 M |
$1.23 M |
$4.96 M |
| Depreciation &
Amortization |
$84.86 M
|
$85.63 M
|
$32.59 M
|
$20.00 M
|
$10.23 M
|
$7.06 M
|
$8.13 M
|
$2.40 M
|
$921,000.00
|
$928,000.00
|
| EBITDA |
$98.26 M
|
$153.44 M
|
$129.19 M
|
$212.40 M
|
$180.42 M
|
$151.51 M
|
$107.67 M
|
$56.62 M
|
$21.77 M
|
-$4.35 M
|
| EBITDA Ratio |
0.16 |
0.22 |
0.21 |
0.4 |
0.43 |
0.39 |
0.34 |
0.26 |
0.13 |
0.2 |
| Operating Income Ratio
|
-0.01
|
0.1
|
0.15
|
0.33
|
0.38
|
0.35
|
0.33
|
0.25
|
0.12
|
0.2
|
| Total Other
Income/Expenses Net |
$8.04 M
|
$14.62 M
|
-$12.85 M
|
-$5.05 M
|
-$1.08 M
|
-$4.27 M
|
$1.08 M
|
-$3.85 M
|
-$6.23 M
|
-$4.36 M
|
| Income Before Tax |
$2.77 M |
$60.74 M |
$73.18 M |
$168.65 M |
$147.49 M |
$140.18 M |
$100.62 M |
$50.37 M |
$14.97 M |
$19.87 M |
| Income Before Tax Ratio
|
0
|
0.09
|
0.13
|
0.32
|
0.38
|
0.34
|
0.33
|
0.23
|
0.1
|
0.16
|
| Income Tax Expense |
$1.45 M |
$32,000.00 |
$19.75 M |
$41.70 M |
$34.43 M |
$29.18 M |
$43.33 M |
-$40.85 M |
$956,000.00 |
$4.04 M |
| Net Income |
$1.32 M |
$60.71 M |
$53.42 M |
$126.95 M |
$113.06 M |
$110.99 M |
$57.28 M |
$91.22 M |
$14.02 M |
$19.87 M |
| Net Income Ratio |
0 |
0.09 |
0.09 |
0.24 |
0.29 |
0.27 |
0.19 |
0.42 |
0.1 |
0.16 |
| EPS |
0.0241 |
1.13 |
1.01 |
2.41 |
2.16 |
2.13 |
1.13 |
1.84 |
0.29 |
0.47 |
| EPS Diluted |
0.0237 |
1.04 |
0.98 |
2.36 |
2.1 |
2.05 |
1.08 |
1.76 |
0.28 |
0.32 |
| Weighted Average Shares
Out |
$54.54 M
|
$53.67 M
|
$53.10 M
|
$52.62 M
|
$52.41 M
|
$51.99 M
|
$50.76 M
|
$49.47 M
|
$47.49 M
|
$42.26 M
|
| Weighted Average Shares
Out Diluted |
$55.51 M
|
$61.68 M
|
$54.36 M
|
$53.69 M
|
$53.82 M
|
$54.10 M
|
$53.30 M
|
$51.71 M
|
$51.16 M
|
$50.58 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
